Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARAVNASDAQ:BGXXNYSE:CLDINASDAQ:CLRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVAravive$0.04$0.04$0.04▼$2.46$2.95M2.19N/AN/ABGXXBright Green$0.05$0.03▼$0.54$11.47M-0.26360,154 shs25,935 shsCLDICalidi Biotherapeutics$0.40-2.2%$0.49$0.35▼$4.90$11.42M1.21883,581 shs264,979 shsCLRBCellectar Biosciences$0.25+1.5%$0.28$0.22▼$3.42$11.48M0.481.15 million shs1.14 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVAravive0.00%0.00%0.00%0.00%0.00%BGXXBright Green0.00%0.00%0.00%+76.47%-71.29%CLDICalidi Biotherapeutics-2.24%-10.04%-16.94%-54.36%+40,119,900.00%CLRBCellectar Biosciences+1.53%-4.20%-18.42%-12.07%-91.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARAVAraviveN/AN/AN/AN/AN/AN/AN/AN/ABGXXBright GreenN/AN/AN/AN/AN/AN/AN/AN/ACLDICalidi Biotherapeutics1.3961 of 5 stars3.50.00.00.00.01.70.6CLRBCellectar Biosciences1.95 of 5 stars3.25.00.00.01.40.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAVAravive 0.00N/AN/AN/ABGXXBright Green 0.00N/AN/AN/ACLDICalidi Biotherapeutics 3.00Buy$10.002,392.52% UpsideCLRBCellectar Biosciences 2.33Hold$12.504,842.67% UpsideCurrent Analyst Ratings BreakdownLatest ARAV, CLDI, CLRB, and BGXX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025CLRBCellectar BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAVAravive$6.99M0.42N/AN/AN/A∞BGXXBright GreenN/AN/AN/AN/A$0.06 per shareN/ACLDICalidi Biotherapeutics$50K228.43N/AN/A($2.32) per share-0.17CLRBCellectar BiosciencesN/AN/AN/AN/A($0.96) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAVAravive-$76.32MN/A0.00∞N/AN/AN/AN/AN/ABGXXBright Green-$13.13M-$0.06N/AN/AN/AN/A-88.37%-55.30%N/ACLDICalidi Biotherapeutics-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/ACLRBCellectar Biosciences-$42.77M-$0.73N/AN/AN/AN/AN/A-191.22%8/11/2025 (Estimated)Latest ARAV, CLDI, CLRB, and BGXX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CLRBCellectar Biosciences-$0.17-$0.13+$0.04-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARAVAraviveN/AN/AN/AN/AN/ABGXXBright GreenN/AN/AN/AN/AN/ACLDICalidi BiotherapeuticsN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAVAraviveN/AN/AN/ABGXXBright GreenN/A0.010.01CLDICalidi BiotherapeuticsN/A0.190.19CLRBCellectar BiosciencesN/A1.771.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAVAravive35.80%BGXXBright Green7.83%CLDICalidi Biotherapeutics12.53%CLRBCellectar Biosciences16.41%Insider OwnershipCompanyInsider OwnershipARAVAravive60.40%BGXXBright Green62.55%CLDICalidi Biotherapeutics24.28%CLRBCellectar Biosciences3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAVAravive2073.56 million29.13 millionNo DataBGXXBright Green2191.17 million71.59 millionNo DataCLDICalidi Biotherapeutics3828.47 million20.04 millionN/ACLRBCellectar Biosciences1046.08 million44.38 millionOptionableARAV, CLDI, CLRB, and BGXX HeadlinesRecent News About These CompaniesWall Street Zen Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB)May 23, 2025 | americanbankingnews.com4 Medical Product Stocks to Watch From a Challenging IndustryMay 21, 2025 | zacks.comMaxim Group Downgrades Cellectar Biosciences (CLRB)May 15, 2025 | msn.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2025 Earnings Call TranscriptMay 14, 2025 | insidermonkey.comCellectar Biosciences Inc (CLRB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...May 14, 2025 | finance.yahoo.comCellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comCellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 13, 2025 | globenewswire.comInsights Ahead: Cellectar Biosciences's Quarterly EarningsMay 12, 2025 | benzinga.comCellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025May 7, 2025 | globenewswire.comCellectar explores strategic options to enhance shareholder valueMay 3, 2025 | uk.investing.comCellectar is seeking strategic alternatives, sinking stockApril 30, 2025 | fiercebiotech.comCellectar Announces Plan to Explore Strategic AlternativesApril 30, 2025 | globenewswire.com4 Medical Product Stocks to Buy From a Challenging IndustryApril 17, 2025 | zacks.comIs Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year?March 18, 2025 | zacks.comCellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call TranscriptMarch 15, 2025 | seekingalpha.comOppenheimer Keeps Their Hold Rating on Cellectar Biosciences (CLRB)March 14, 2025 | markets.businessinsider.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | insidermonkey.comQ4 2024 Cellectar Biosciences Inc Earnings CallMarch 14, 2025 | uk.finance.yahoo.comCellectar Biosciences reports FY24 EPS ($1.40), consensus ($1.57)March 13, 2025 | markets.businessinsider.comCellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate UpdateMarch 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARAV, CLDI, CLRB, and BGXX Company DescriptionsAravive NASDAQ:ARAV$0.04 0.00 (0.00%) As of 05/23/2025Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Bright Green NASDAQ:BGXXBright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.Calidi Biotherapeutics NYSE:CLDI$0.40 -0.01 (-2.24%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$0.41 +0.00 (+1.20%) As of 05/27/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.Cellectar Biosciences NASDAQ:CLRB$0.25 +0.00 (+1.53%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$0.26 +0.00 (+1.23%) As of 05/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
